GRCE
Grace Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.89 / 10
Netural
Fund flow evaluation: 7.78/10 reflecting robust fund flow characteristics. Constructive Medium trends face headwinds from adverse overall, block, Small, Large, and Extra-large developments, indicating positive money flow direction. Research analyst consensus shows overwhelmingly bullish analyst consensus, demonstrating strong conviction. Current ratings: Strong Buy(100.0%) across 1 coverage providers, supported by 0.00 historical weighted rating.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-02-18
InstitutionHC Wainwright & Co.
Times predicted1
Historical Win Rate0.0%
What is the analyst consensus for GRCE?
- GRCE holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.89/10 (Netural).
